Phase II trial of topotecan administered as a 72-hour continuous infusion in children with refractory solid tumors: A collaborative pediatric branch, national cancer institute, and children's cancer group study

Clinical Cancer Research

Volumn 4, Issue 2, 1998, Pages 357-360

  Blaney, Susan M ^a,d   Needle, Michael N ^b   Gillespie, Andy ^a   Sato, Judith K ^b   Reaman, Gregory H ^b   Berg, Stacey L ^a,d   Adamson, Peter C ^a   Krailo, Mark D ^b,c   Bleyer, W Archie ^b   Poplack, David G ^d   Balis, Frank M ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b CHILDREN S ONCOLOGY GROUP   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^d TEXAS CHILDREN S CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TOPOTECAN;

ADOLESCENT; ADULT; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CHILD; CHILDHOOD CANCER; CLINICAL TRIAL; CONTINUOUS INFUSION; DRUG EFFICACY; DRUG RESPONSE; DRUG SCREENING; EWING SARCOMA; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; NAUSEA; NEUROBLASTOMA; NEUROECTODERM TUMOR; OSTEOSARCOMA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SOFT TISSUE SARCOMA; SOLID TUMOR; VOMITING;

ADOLESCENT; ADULT; ANTINEOPLASTIC AGENTS; BONE NEOPLASMS; CHILD; CHILD, PRESCHOOL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INFANT; INFUSIONS, INTRAVENOUS; MALE; NEOPLASMS; NEUROBLASTOMA; NEUROECTODERMAL TUMORS, PRIMITIVE, PERIPHERAL; OSTEOSARCOMA; RHABDOMYOSARCOMA; SARCOMA, EWING'S; SOFT TISSUE NEOPLASMS; TOPOTECAN;

EID: 0031939569     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Hertzberg, R. P., Caranfa, M. J., Holden, K. G., Jakas, D. R., Gallagher, G., Mattem, M. R., Mong, S. M., Bartus, J. O., Johnson, R. K., and Kingsbury, W. D. Modification of the hydroxy lactone ring of camptothecin: inhibition of mammalian topoisomerase I and biological activity. J. Med. Chem., 32: 715-720, 1989.
2. Liu, L. DNA topoisomerase poisons as antitumor drugs. Annu. Rev. Biochem., 58: 351-375, 1989.
3. Houghton, P., Cheshire, P., Myers, L., Stewart, C., Synold, T., and Houghton, J. Evaluation of 9-dimethylaminomethyl-10-hydroxycamptothecin against xenografts derived from adult and childhood solid tumors. Cancer Chemother. Pharmacol., 31: 229-239, 1992.
4. Houghton, P., Cheshire, P., Hallman, J., Lutz, L., Friedman, H., Danks, M., and Houghton, J. Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors. Cancer Chemother. Pharmacol., 36: 393-403, 1995.
5. Blaney, S. M., Balis, F. M., Cole, D. E., Craig, C., Reid, J. M., Ames, M. M., Krailo, M., Reaman, G., Hammond, D., and Poplack, D. G. Pediatric Phase I trial and pharmacokinetic study of topotecan administered as a 24-hour continuous infusion. Cancer Res., 53: 1032-1036, 1993.
6. Pratt, C. B., Stewart, C., Santana, V. M., Bowman, L., Furman, W., Ochs, J., Marina, N., Kuttesch, J. F., Heideman, R., Sandlund, J. T., Avery, L., and Meyer, W. H. Phase I study of topotecan for pediatric patients with malignant solid tumors. J. Clin. Oncol., 12: 539-543, 1994.
7. Burris, H., Awada, A., Kuhn, J., Eckardt, J., Cobb, P., Rinaldi, D., Fields, S., Smith, L., and Von Hoff, D. Phase I and pharmacokinetic studies of topotecan administered as a 72 or 120 h continuous infusion. Anticancer Drugs, 5; 394-402, 1994.
8. Carde, P., MacKintosh, F. R., and Rosenberg, S. A. A dose and time response analysis of the treatment of Hodgkin's disease with MOPP chemotherapy. J. Clin. Oncol., 1: 146-153, 1983.
9. Hryniuk, W., and Bush, H. The importance of dose intensity in chemotherapy of metastatic breast cancer. J. Clin. Oncol., 2: 1281-1288, 1984.
10. Smith, M., Ungerleider, R., Horowitz, M., and Simon, R. Influence of doxorubicin dose intensity on response and outcome for patients with osteogenic sarcoma and Ewing's sarcoma. J. Natl. Cancer Inst., 83: 1460-1470, 1991.
11. Blaney, S. M., Phillips, P. C., Packer, R. J., Heideman, R. L., Berg, S. L., Adamson, P. C., Allen, J. C., Sallan, S. E., Jakacki, R. I., Lange, B. J., Reaman, G. H., Horowitz, M. E., Poplack, D. G., and Balis, F. M. Phase II evaluation of topotecan for pediatric central nervous system tumors. Cancer (Phila.), 78: 527-531, 1996.
12. National Cancer Institute. Guidelines for Reporting of Adverse Drug Reactions, Bethesda, MD, Division of Cancer Treatment, National Cancer Institute, 1988.